Enhancing the potency of HBV DNA vaccines using fusion genes of HBV‐specific antigens and the N‐terminal fragment of gp96

Abstract

We constructed highly immunogenic fusions by linking the N-terminal fragment of gp96 to HBV antigens. Our results imply that the N-terminal fragment of gp96 may be used as a molecular adjuvant to enhance the potency of DNA vaccines.